TickerFactsScreenerDevelopers

Altimmune, Inc. (ALT) — Cash & Equivalents

Annual figures by fiscal year, from SEC filings.

2009: $2.67M2010: $11.79M2011: $11.24M2012: $12.70M2013: $10.48M2014: $18.64M2015: $15.57M2016: $2.88M2017: $8.77M2018: $33.72M2019: $8.96M2020: $115.92M2021: $190.30M2022: $111.10M2023: $135.12M2024: $36.93M2025: $43.76M$43.76M
2009Cash & Equivalents (USD)2025
Fiscal YearCash & EquivalentsChange YoY
2025$43.76M+18.5%
2024$36.93M-72.7%
2023$135.12M+21.6%
2022$111.10M-41.6%
2021$190.30M+64.2%
2020$115.92M+1193.3%
2019$8.96M-73.4%
2018$33.72M+284.5%
2017$8.77M+204.9%
2016$2.88M-81.5%
2015$15.57M-16.5%
2014$18.64M+77.9%
2013$10.48M-17.5%
2012$12.70M+13.0%
2011$11.24M-4.7%
2010$11.79M+340.8%
2009$2.67M—